Endonovo Therapeutics Inc (ENDV)

[brojazzy]

Scam!

[Craig305]

ENDV has Greg McAndrews & Associates listed as their media contact yet GM&A does not have ENDV listed as a current client on their own website.

[retired early]

He's a leach.

[brojazzy]

What a complete scam this is, how in the world is the loser CEO not in prison yet

[Craig305]

You were not wrong about the compensation.
Per the offering details just released......how can he justify such large compensation expense when absolutely "nothing" happened in 2022.
I suppose Ira received a nice bonus to join ENDV late in 2022.

Our operating expenses increased by $1,105,038 or 48.4% to $3,389,705 in 2022 compared to $2,284,667 in 2021. The operating expenses were comprised primarily of consulting fees, professional fees, and stock-based compensation. This change was due primarily to an increase in stock-based compensation of approximately $1.2 million.

[Craig305]

ENDV has filed a preliminary offering.

Endonovo Therapeutics Inc., a Delaware corporation (the “Company”, “ENDV”, “we”, or “our”), is offering up to a maximum of 220,000,000 shares (the “Maximum Amount”) of our Common Stock, par value $0.0001 per share (the “Shares”) to be sold in this offering (the “Offering”). The Shares are tentatively being offered at a purchase price of $0.01 per Share, for gross proceeds of up to $5,000,000 (the “Maximum Amount”), pursuant to this Offering Circular (this “Offering Circular”). Before this Offering is qualified, the Company will pick a final price for the shares (the “Offering Price”) which we anticipate will be between $0.01 and $0.05 per share.

[retired early]

Number of employees: 0 (2022)
Subsidiaries: IP Resources International Inc., WeHealAnimals, Inc., The Aviva Companies Corporation
Disclaimer
Financials
Quarterly financials
(USD) Jun 2023 Y/Y
Revenue 45.2K 6853.85%
Net income 2.06M 181.69%
Diluted EPS -0.01 50%
Net profit margin 4,565.62% 101.17%

Not bad for zero employees :) It's an ATM folks.

[John_Vallay]

My OPINION about Endonovo - the company has never had sales.

My OPINION about ENDV stock - the stock has never increased, in fact it has a history from the day that Alan Collier took over as CEO that the stock has been in a rapid decline and the only reason they are not on the pink sheets or revoked by the SEC is because they continue to do reverse splits.

MY OPINION about Sofpulse - The product is a failure, or simply doesn't work. This opinion is based on Ivivi trying to make a go of it and failed and the fact that Alan Collier has announced numerous distribution deals with many different companies and a few years ago he even hired in-house sales people, neither has produced any sales.

My OPINION on the future - Alan Collier will continue to try to run the business and get loans or convertible notes because that brings in cash so he can pay himself a salary and receive health benefits for himself and his family. This process is actually legal, but only successful if people buy the stock on the open market because the convertible note holders only make money if there is trading in the stock because they get the stock at a big discount to market and when they get the stock they sell it, because investors buy the stock on the open market and inevitably lose money.

My OPINION about anyone being positive on this message board about the company or stock - People that are paid for a service are biased, and therefore have no worth or legitimacy when it comes to discussing their opinions and suggestions when it comes to stock price, market cap or anything related to buying, selling or holding a stock that they are being paid to support, promote or encourage others to buy.

I don't know who bought the 306,000 shares that were traded so far today, but it only means $3,600 dollars worth of stock traded. It's very disappointing that some people do not understand investing because ENDV is not a good investment.

This is my last post on this message board because its disheartening to see people lose money to what is a legal scam like convertible notes and toxic financings that Alan Collier has done through Endonovo. It's LEGAL, but a shame.

[Biotech_Tradez]

LOL, Awfully silent about that mess of a 10Q.

But, quick to start pumping the stock based on another PR. What is ENDV's history of PR's? All lies.

[Cornerstone_Marketing]

Inclusion in the Federal system has many benefits including showing legitimacy of the device and its uses to the public “before” its pending DTC launch and telehealth launch coming soon.

As sofpulse expands worldwide and gains approval in many countries systems and marketplaces acceptance of this devices already proven many uses and applications will lead to sales and revenues from worldwide distribution channels.

REVENUE will be key for the future of the company and this is just a small step towards that but a huge one.

[Biotech_Tradez]

PR is a fluff piece distraction from yesterday's terrible 10Q.

Full of lies, damn lies, exaggerations and misrepresentations. It's purpose is to distract hence why it was timed to be released right after the 10q.

No revenue has been generated and being included in the FSS does not mean revenue will be generated. It is simply a requirement to be able to sell to the VA through a process that ensures they get fair pricing due to their bulk purchasing power.

Notice the train of events to manipulate the stock. First someone conveniently buys to make the stock close up 17%, then they release the 10Q aftermarket and lastly premarket PR is released next day to pump the stock. Looks like they are desperate to keep this from going sub-penny again.

[Craig305]

Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution

Los Angeles, CA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) -- a US-based commercial medical device company -- today announced its inclusion on the Federal Supply Schedule (FSS) for SofPulse® Pulsed Electro Magnetic Field (PEMF) medical devices for distribution throughout the Federal healthcare supply channels.

The listing was spearheaded by Endonovo’s partner, Academy Medical Inc, a Service-Disabled Veteran-Owned Small Business (SDVOSB) government reseller. Academy Medical’s efforts to secure SofPulse® on the exclusive FSS is the first of many strategic moves for Endonovo to streamline the distribution of its medical products throughout government healthcare systems.

Expanding Distribution for FDA-Cleared Surgical Solutions

SofPulse® is an FDA-Cleared medical device which is recognized for its exceptional efficacy for postoperative reduction of pain and edema (inflammation). Clinical studies and patient use have shown that PEMF has the capacity to alleviate pain, promote recovery and enhance overall patient well-being. As SofPulse® is non-invasive, opioid-free and with its potential to speed up recovery, it sets it apart in the medical technology landscape.

The inclusion of SofPulse® on the FSS signifies not only a stamp of approval from Federal authorities, but further affirms the Company’s objective of having SofPulse® widely distributed within the government healthcare sectors.

"This endorsement reaffirms our commitment to delivering cutting-edge solutions that cater to diverse healthcare needs” according to Ira Weisberg, President of Endonovo’s Medical Division. Listing on the FSS is a testament to the efficacy and potential of SofPulse® within the U.S. and global medical community,” he pointed out.

SofPulse® Positioned for Accelerated Revenue Growth

SofPulse® listing on the FSS places its proven PEMF recovery technology at the forefront of distribution, paving the way for exponential growth within the Veterans Administration (VA) and Department of Defense as well as other governmental healthcare sectors. The VA utilizes the FSS to make available a wide range of authorized products and services on an ongoing basis.

“Securing a coveted place on the prestigious FSS for SofPulse® PEMF products is a significant milestone and will help us expand our distribution, growth and revenues from our government healthcare contracts,” Weisberg said.

Opportunity to Capitalize on Untapped PEMF Market

The FSS was established as a means of streamlining government purchases of commercial products. Having SofPulse® included in the FSS will provide for expanded opportunities for the distribution of the Company’s innovative PEMF products throughout the VA healthcare system, which services over 16.5 million patients yearly. Inclusion in the FSS offers companies like Endonovo the opportunity to distribute and generate revenue through sales and distribution to the VA, Department of Defense, Federal and executive agencies in addition to other healthcare agencies.

As Endonovo navigates this new phase of Federal expansion, the Company remains resolute in its mission to enhance patient care for our military heroes and their families. Expanding Federal contracts is important to positioning Endonovo to seize anticipated expansion for active and non-active military personnel surgical, medical and wound care needs. Through the FSS, SofPulse® will gain increased visibility to serve a wider range of patients., strengthening its position as a non-opioid medical solution within the Government medical technology sector.

Plans for Future Expansion of Government Contracts

Endonovo has identified numerous governmental healthcare contracts for the expansion of distribution throughout the government healthcare sectors. Through Academy Medical, additional future government contracts targeted include: Strategic Acquisition Center (SAC), National Acquisition Center (NAC) and the defense agencies and Department of Defense Field Activities (DAFA) distribution schedules. Each federal contract being targeted affords Endonovo the opportunity allows Endonovo and SofPulse to reach a broader audience, including hundreds of federal healthcare facilities throughout the US and the world. The Company aims to leverage the power and influence of the Federal government's buying process to provide SofPulse® to healthcare facilities and patients not currently being serviced.

Weisberg concluded: “To streamline our government distribution expansion, we have established pre-negotiated prices, terms, deliverables, warranties and other details to aid in making the purchasing process more straightforward. Our Company is starting to realize the benefits of our partnership with Academy Medical with being able to service new distribution channels as well as increased revenue.”

About Endonovo Therapeutics, Inc.

Endonovo Therapeutics is currently structured into two divisions: Legacy – a commercial-stage developer primarily of noninvasive wearable Electroceuticals® therapeutic devices for pain relief, general wellness and wound curatives with many of its products marketed under the SofPulse® brand name; and its Build Up Strategy – acquiring complementary specialty service providers in the medical technology and construction industries.

About Academy Medical, Inc.

Academy Medical is a premier Service-Disabled Veteran-Owned Small Business and distributor of medical-surgical equipment and supplies to the Federal government. As a government procurement partner with industry expertise and access to advanced technology, Academy Medical’s mission is to leverage its preferred status as an SDVOSB to create a streamlined, more cost-effective process for its government customers and supplier partners.

Academy Medical is headquartered in West Palm Beach, Florida. Learn more about partnering with the company in its service-driven business at www.academymedical.net.

[Biotech_Tradez]

BUYER BEWARE!!! ENDV IS INSOLVENT AND DILUTING LIKE CRAZY

1.3 billion fully diluted shares. 317 Million shares currently outstanding, including another 30 million shares gifted to management.

less than $1 million in assets, but the following liabilities:

- $1 million in accounts payable and accrued liabilities
- $4 million in accrued interest owed to the convertible note holders
- $7 million in notes payable of which $6.7 million are past due.

This company is heading to a bankruptcy and asset sale to settle their debts. Management is simply robbing the bank before they head out the door.

[Biotech_Tradez]

BUYER BEWARE!! CEO and his cronies have given themselves an additional 29.6 MILLION shares.

They are literally stealing from the shareholders. They have done NOTHING to earn a single cent, yet they are just printing shares for everyone.

[Biotech_Tradez]

Basically no new revenue, its is merely recognizing a part of the previously announced $300k.

This company is insolvent. $32K in cash and $900k in assets yet they owe over $4m in accrued interest alone and another $7m in notes.

They are going so low as to now guarantee profits of 18% to its note holders or they issue them more shares to make up the difference. It is an unethical and questionable way to weasel around laws preventing people from guaranteeing investments, which is ILLEGAL!

[Craig305]

2Q is out. $45K in sales for Q2

[Craig305]

It is looking like we have to wait until Monday for the 10-Q release.

[Craig305]

This is more like it.

I know what you're thinking. "Has Crash and Berns" been fully paid yet? Well, to tell you the truth, in all this recent selling of shares I kind of lost track myself. But being as ENDV is a share selling company and can dilute your entire investment to 99% loss, you've got to ask yourself one question: Do you feel lucky buying shares now? Well, do ya punk?

[John_Vallay]

On August 8th Endonovo issued a press release and had this line included in the press release:
The Company has made significant strides in multiple areas of sales, marketing, branding, management and financing. These milestones give management confidence for sustained growth and substantial revenues. The Company is focusing on its FDA Cleared Pulsed Electro Magnetic Field (PEMF) technologies and the telehealth industries.

Significant strides in sales. That means they will be announcing sales, like lots of revenues.
They used the word SIGNIFICANT.

If they increased sales significantly, then I applaud them.
If they didn't increase sales then Alan Collier is either a stupid human being, terrible CEO or just issues fluff press releases to try to get people to buy the stock so he doesn't get booted off of the OTCQB.

They issued the press release on August 8, which is over a month AFTER THE QUARTER ENDED so he knew what the sales were at the time he issued the press release so lets see what type of a person Alan Collier is.

[retired early]

Now's your chance. Do you feel lucky? Well do you p--k? :)

[brojazzy]

Lock up the fake ass mgmt here, selling shares shouldn’t be a business

[Nikodemos]

TAPE-SNAP! Nearly 5:1 DUMPING SELLS to buys...

https://ih.advfn.com/stock-market/USOTC/endonovo-therapeutics-qb-ENDV/trades



[] So far the interest rates & notes are pretty dang lengthy!
[] The CASH BURN is ridiculous
[] Most notes carry 12-18% interest
...which is also REDICULOUS!



Just started digging-in!!


So far... I'm NOT seeing the appeal...

Plus:
[] Way higher than normal volume
[] To the DOWNSIDE
https://finance.yahoo.com/quote/ENDV/history?p=ENDV

[] Chart support BREAKDOWN...
[] 50dma breaks DOWN through 200dma is NEVER GOOD!


[] And if the $0.008's don't hold
[] for a TRIPLE BOTTOM on the yearly...


[] GET READY for another 25% haircut down to $0.006 test!






The trend here appears to be DOWN...



And the problem is it appears to be ACCELERATING DOWNWARDS....!!


Most of that VWAP is crashing that bid...



But if this is another "Cornerstone_Marketing" play, then why am I NOT surprised! Smdh...


LIEn Jeff
soup-&-samwich Shane
& their FAKE (bought) "FOLLOWERS"


These guys appear to be on QUITE THE ROLL .... TOILET ROLL!!









$ENDV



...

[Biotech_Tradez]

Someone trying to snipe 2million shares at $0.0001 LOL!

I bet PennystockSniper is hoping for another drop so he can swoop up shares cheap and then come back to pump the stock to a bunch of suckers.

[Craig305]

Ouch....now we can see why Alan was trying so hard not to pay Gary. Those payments must be happening with Gary's silence and this slide in SP.

[Biotech_Tradez]

Brace yourself for the bad news in the footnotes & the theft from shareholders in the form of stock bonuses and options.

[Craig305]

NT filed. Q will be delayed another 5 days.

[Craig305]

Magniant still lists Sofpulse as a product they market. They were also targeting the VA.

Alan,
What happened to this partnership?
https://www.magniant.com/endonovo-release

[brojazzy]

Endless dilution

[Biotech_Tradez]

What happened to all the people that ran ENDV when they acquired these PEMF assets?

I never saw a PR or even a note in the filings. Their Chief Medical Officer disappeared, their President Michael Mann resigned, their COO disappeared, their scientific consultants also disappeared. Did the Company not pay them or did they get fired? Collier seems to try to run the company by himself to save money and pay himself, but that has resulted in zero progress. He should probably look to get some of those people back on board. Collier's specialty seems to be to raise dilutive capital and not much else, so it would be wise for him to at least try to get people to actually put some money to use. I don't see Ira bringing much value given his age, which means he is just a name otherwise we would have already seen an investment from institutional investors.

I looked into Telemedicine/telehealth and ENDV will not be able to do anything without a huge capital injection. Not only do they need key hires to develop the platform, which includes all the backend work and electronic health records, but they also need personnel to deal with the regulatory requirements. Without $10-15 million in dedicated capital for it I don't see it as even remotely possible.

[brojazzy]

Close low of the day…..TRASH!!

[Craig305]

I hope the recent tweet about an "exciting announcement" was not for this PR.
This PR was a rehash of all past PRs just as you said.

They should have mentioned status of the Ocean Tomo analysis which was "expected to be completed in Q1" as quoted by Alan.
There should have been an update on this.

Just another example of a delay or a cancelled event that is not addressed and swept under the rug.

[John_Vallay]

I do have a question that needs to be answered

In the press release is the following line: The Company has made significant strides in multiple areas of sales, marketing, branding, management and financing.


I did not see anywhere in the press release about any type of financing?

[Biotech_Tradez]

Deal fell through because ENDV has no money, no ability to raise money and tens of millions in debt!

Collier will simply pretend it didn't happen.

[Craig305]

What happened with the "signing of a definitive purchase agreement for Endonovo to acquire all of Western Star’s assets and business operations."???

This was PR'd 11 months ago.
A good "update" would inform shareholders of pending acquisitions that seemed to be imminent and talked about millions in revenue.

We will have to assume that deal fell through and is no longer happening. Collier never addresses shareholders when something bad happens or does not happen at all. It appears Western Star has been swept under the rug.

[Biotech_Tradez]

PennyStockSniper trying too hard on this one, lol. Nothing new in this PR.

Simply a summary of a bunch of other PR's. Notice no new revenue. Notice no funding to keep the lights on. The dilution happening at the moment is to pay for the 10Q, which will contain a bunch bad news buried in the footnotes.

[Cornerstone_Marketing]

Very nice company update. Seems like they are moving forward on the plan.
Excited to see where this goes in the coming Q’s

[Craig305]

Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update

Los Angeles, CA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB: ENDV) -- commercial developer of medical technology-- is proud to announce a series of advancements in the first half of 2023.

The Company has made significant strides in multiple areas of sales, marketing, branding, management and financing. These milestones give management confidence for sustained growth and substantial revenues. The Company is focusing on its FDA Cleared Pulsed Electro Magnetic Field (PEMF) technologies and the telehealth industries.

Hiring President to Guide SofPulse® Global Growth

Endonovo's hiring of Ira Weisberg as President and Chief Commercial Officer in December 2022 has proven to be successful. The strategic hiring of Weisberg to lead sales, marketing and brand initiatives is set to drive Endonovo's expansion and distribution efforts.

Weisberg’s distinguished career spans over four decades in healthcare and pharmaceutical management, business development, finance, sales and marketing. He brings a wealth of expertise to the table and has helped to propel Endonovo's non-opioid pain management initiatives and the expansion of PEMF therapies both domestically and internationally.

Market Penetration and Brand Expansion

Endonovo is successfully expanding its reach to new regions and increasing brand awareness domestically and internationally. The Company's innovative approach to pain relief and non-opioid alternatives has garnered widespread attention in expanding medical markets. The Company has been successful in expanding contracts to grow market and brand initiatives to better service in-patient, out-patient, wellness and direct-to-consumer markets.

“Management believes that the actions taken during the first two quarters of 2023 have strategically positioned our products to make substantial revenues in the growing $400 billion pain/telehealth markets,” Weisberg stated.

Expanded Distribution for Veterans and Military Personnel

Endonovo continues to be dedicated to supporting veterans and active-duty military personnel who have served our nation with honor and dedication. In the first quarter of 2023, we solidified a strategic partnership with Academy Medical, a leading distribution company, serving Veterans and Dept of Defense patients. The Veteran Health Administration (VA) is its largest customer.

The agreement can help to play a pivotal role in delivering essential PEMF- therapies and medical products to government facilities. To prepare for scalable growth, Endonovo is in the process of building dedicated sales and marketing initiatives to support the growth of its expanded distribution contracts.

"We are thrilled with the progress we have made in the last six months, and we remain steadfast in our mission to transform pain and inflammation relief and develop telehealth solutions. With our pioneering PEMF technology and strategic initiatives, we are poised for continued growth and success,” Weisberg said.

Scientific Research and Advancements in Patent Technology

The Company looks to continue its research and development efforts to develop through its PEMF patents to address Central Nervous System (CNS) disorders and reduce inflammation symptoms related to Traumatic Brain Injury (TBI), Post-Concussion Syndrome (PCS), Multiple Sclerosis (MS), dementia, Alzheimer’s disease and ischemic stroke.

Present and past studies utilizing SofPulse® at highly regarded institutions, including Stanford University and Columbia University, further demonstrate our commitment to evidence-driven medical solutions.

Our ongoing scientific research has positioned us to seize new revenue opportunities in the rapidly expanding CNS and TBI global treatment markets. According to Grand View Research, the global market for CNS therapeutics was valued at $116.2 billion in 2020, projected to grow at a remarkable Compound Annual Growth Rate (CAGR) of 7.4% from 2021 to 2028, reaching $214.8 billion in 2028. The market for TBI treatment alone is estimated to surge from $3.1 billion in 2021 to $4.5 billion in 2026, as reported by Global Market Estimates.

Advancement of TBI Research

Over the past six months, SofPulse® PEMF Therapy has garnered overwhelmingly positive responses from renowned clinical researchers and top global cognitive institutes to evaluate the incredible potential in alleviating TBI symptoms. Proposed studies aim to target acute head injuries, including concussions and Post-Concussion Syndrome (PCS), with expected results to alleviate headaches, dizziness and cognitive impairment.

Endonovo influencer David Irving, a former NFL Dallas Cowboy and Las Vegas Raider Defensive lineman, brings personal experience to the forefront. Having faced over 20 concussions by the age of 26, David joins us to recruit fellow athletes experiencing ongoing TBI symptoms for our transformative studies.

Empowering Healthcare Solutions Worldwide

Endonovo's international expansion strategy is accelerating. In partnership with an international distribution company, EverMed Inc, we eagerly await Taiwan FDA approval to bring the groundbreaking SofPulse® medical device to the country. Our distribution efforts in Mexico and Costa Rica have already resulted in substantial orders, generating hundreds of thousands of dollars in revenue.

Moving forward, the Company’s sights are set on expansion into key markets such as: Australia, South America, Europe, South Korea, Thailand and Singapore. Initial response and contract negotiations have exhibited that the global medical markets are taking notice of our innovative pain relief solutions and non-opioid alternatives. Endonovo looks to expand international distribution efforts and believes they will be driving our mission to revolutionize healthcare accessibility worldwide. Together with our international partners, we are poised to shape a healthier, pain-free future for people across the globe.

Telehealth Offers Healthcare Access Anywhere, Anytime

The future of healthcare is taking a bold leap forward with Endonovo's telehealth initiative. Over the first half of 2023, we have achieved significant milestones in designing and developing a comprehensive telemedicine platform set to redefine how medical services and cutting-edge devices reach the masses.

Through our telehealth platform, veterans, active-duty personnel, and civilians alike will have seamless access to medical guidance and advanced pain management solutions from the comfort of their homes or “on the go”. To realize this ambitious endeavor, Endonovo has partnered with a leading telehealth developer known for pioneering transformative solutions in the Telemedicine Industry.

Weisberg concluded his review of the first half of 2023: “SofPulse® is the only FDA-cleared, non-narcotic, holistic pain-relieving product able to get pain sufferers back to their lives faster with an improved quality of life. Our PEMF therapies bolster our belief that better access to our therapies will lead us to live better lives.”

[Biotech_Tradez]

A fool and his money are soon parted!

An instant 40% loss on his buy. It is 100% ENDV doing the buying to prop up their failing company.

[retired early]

Come on! Who's the guy who just bought $350 worth. I got this bridge that has to go. :)

[brojazzy]

This trash headed back sub penny and ultimately yet ANOTHER reverse split

[Biotech_Tradez]

Penny Stock companies break the law every day. That is why FINRA/SEC is going after them.

The Tweet is an obvious response to the stocks decline. It is a pathetic attempt to create speculation as to what the "pending announcement" will be. Your comment is very predictable given you are a compensated marketer of the stock.

[Cornerstone_Marketing]

Wow your really reaching in that statement. Seems like a fairly common updates coming tweet to me.

Tons of these every day. Many from Nasdaq companies. But I guess if you eat lemons for breakfast….

[Biotech_Tradez]

Tweet potentially violates securities laws because it is an obvious attempt to manipulate the market.

It triggers speculation. If they have an announcement, they can issue a press release and/or an 8K.

[Biotech_Tradez]

Reeks of desperation. Collier will say anything to keep the stock from going sub-penny.

[Craig305]

Tweet from ENDV

Please stay tuned. Very exciting times at $ENDV we have a pending announcement as well as several updates coming soon!

[Craig305]

My vote is for #2.
With Crash and Berns on complete radio silence, perhaps that was part of the deal to get shares for sale.
If he did get shares....better have a PR soon or this will go sub penny with little bid support.

[Biotech_Tradez]

Looks like either PennyStockSniper dumped his shares or Crazy Bernie was allowed to convert his stock.

[John_Vallay]

Direct to consumer is a costly endeavor that would probably be in the $30-$50 customer acquisition cost when all is said and done. It would be great if Endonovo can start selling at amazon.com, but the product is not approved for such sales and distribution.

But that does not matter because the medical device has not been approved by the FDA for that type of sales and distribution. They have to go through a prescription.

I also question if the device has any viability. The reason I say that is because sales have been zero. The VA hospital, which is allowed to prescribe it to their patients has zero sales. Keep in mind the VA hospital has a large budget for medical devices to be used on their patients.

It's easy for the company or a paid representative to tell you how great the product is, or have a third party boast about the usage of a product, BUT SALES IS THE ONLY LEGITIMATE AND PROOF OF CONCEPT. Words and meaningless, sales have value above and beyond just money.

If the product is that good, as some have claimed, then I ask why is the FDA not allowing it to be sold directly to consumers?

[Biotech_Tradez]

ENDV doesn't have OTC clearance from the FDA.

They have to apply for it. So far they have not filed for anything or we would have seen a press release to pump the stock. The reality is that they don't have the money to do anything, even paying for the quarterly filings is getting tougher by the day.

Look at what BIEL did to get OTC clearance. They conducted a clinical trial for back pain and even then its not that easy to get and sales really don't increase because they don't have the marketing budget of a large manufacturer like for example J&J.

[Craig305]

The Direct To Consumer should help increase sales. The prescription requirement makes it harder for people to acquire and try it.

Do you know what changes have to be made to remove the prescription requirement and allow it to be freely available?
Why was it originally setup that way by Ivivi?